The new stomach cancer drug is examined as principal, reducing the risk of death for 42 percent patients

The new stomach cancer drug is examined as principal, reducing the risk of death for 42 percent patients

The new stomach cancer drug is examined as principal, reducing the risk of death for 42 percent patients

The pharmaceutical company AstraZeneca has announced that experimental medicine sonnesitoug vdoti has received priority screening status from the American Food and Barnat Administration ( The FDA, to treat some patients with advanced stomach cancer.

The results of the clinical study of the third stage showed that the drug reduced the risk of dying for patients by 42 percent compared with other treatments used in the study.

3M Express sponsor

According to the results, patients who took the drug had an average survival of 10.6 months, compared to 6.4 months in those who received alternative treatment.

The medicine targets a particular protein in cancer cells in order to attack the tumor more directly.

The FDA’s final decision is expected during the second quarter of 2027. 

The signal where the truth speaks before the news!

/Gazeta Sinjali/

Source Layer: Signal

Read more

New health doctors and professionals protest in Pristina again today

New health doctors and professionals protest in Pristina again today

One of the richest protein foods here is the ideal time to eat Greek yogurt

One of the richest protein foods here is the ideal time to eat Greek yogurt

Rector UP’s responds to student concerns, promises special regulations for medicine and veterina

Rector UP’s responds to student concerns, promises special regulations for medicine and veterina